Gwenn Hansen - Jan 30, 2023 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen
Stock symbol
NRIX
Transactions as of
Jan 30, 2023
Transactions value $
-$16,633
Form type
4
Date filed
2/1/2023, 03:15 PM
Previous filing
Nov 1, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $0 +3.21K +15.12% $0.00 24.4K Jan 30, 2023 Direct
transaction NRIX Common Stock Sale -$16.6K -1.41K -5.78% $11.78 23K Jan 30, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Restricted Stock Units Options Exercise $0 -3.21K -7.69% $0.00 38.5K Jan 30, 2023 Common Stock 3.21K $0.00 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F5 RSUs do not expire; they either vest or are canceled prior to the vest date.